Zobrazeno 1 - 3
of 3
pro vyhledávání: '"Thomas M. Feldsien"'
Autor:
Axel H. Meyer, Thomas M. Feldsien, Mario Mezler, Christopher Untucht, Ramakrishna Venugopalan, Didier R. Lefebvre
Publikováno v:
Pharmaceutics, Vol 15, Iss 4, p 1100 (2023)
The blood-brain barrier (BBB) is a major hurdle for the development of systemically delivered drugs against diseases of the central nervous system (CNS). Because of this barrier there is still a huge unmet need for the treatment of these diseases, de
Externí odkaz:
https://doaj.org/article/45d3488e046e4470a84c1662b355c574
Autor:
Kendra A Porath, Michael S Regan, Jessica I Griffith, Sonia Jain, Sylwia A Stopka, Danielle M Burgenske, Katrina K Bakken, Brett L Carlson, Paul A Decker, Rachael A Vaubel, Sonja Dragojevic, Ann C Mladek, Margaret A Connors, Zeng Hu, Lihong He, Gaspar J Kitange, Shiv K Gupta, Thomas M Feldsien, Didier R Lefebvre, Nathalie Y R Agar, Jeanette E Eckel-Passow, Edward B Reilly, William F Elmquist, Jann N Sarkaria
Publikováno v:
Neuro-oncology advances. 4(1)
Background EGFR targeting antibody-drug conjugates (ADCs) are highly effective against EGFR-amplified tumors, but poor distribution across the blood–brain barrier (BBB) limits their efficacy in glioblastoma (GBM) when administered systemically. We
Autor:
Kendra A. Porath, Ann Mladek, Rachael A. Vaubel, Michael S. Regan, Sonia Jain, Danielle Burgenske, Katrina Bakken, Brett Carlson, Margaret Connors, Zeng Hu, Lihong He, Paul A. Decker, Gaspar Kitange, Shiv Gupta, Nathalie Y. Agar, Thomas M. Feldsien, Didier R. Lefebvre, Jann N. Sarkaria
Publikováno v:
Cancer Research. 82:334-334
Introduction: EGFR targeted antibody-drug conjugates (ADCs) show promise as a novel treatment in a subset of glioblastoma (GBM). Two EGFR targeting ADCs include first generation Depatux-M, with an antimitotic toxin monomethyl auristatin F (MMAF), and